Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

H. Yoshioka, M. Shimokawa, T. Seto, S. Morita, Y. Yatabe, I. Okamoto, J. Tsurutani, M. Satouchi, T. Hirashima, S. Atagi, K. Shibata, H. Saito, S. Toyooka, N. Yamamoto, K. Nakagawa, T. Mitsudomi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. Patients and methods: Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. Results: OS events in the G group and CD group were 68 (79.1%) out of 86 and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95% confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. Conclusion: G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease. This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.

Original languageEnglish
Pages (from-to)1978-1984
Number of pages7
JournalAnnals of Oncology
Volume30
Issue number12
DOIs
Publication statusPublished - Dec 1 2019

Fingerprint

docetaxel
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Cisplatin
Mutation
Survival
Recurrence
Therapeutics
Confidence Intervals
Information Services
Survival Analysis
gefitinib
Proportional Hazards Models
Protein-Tyrosine Kinases
Disease-Free Survival
Japan
Multivariate Analysis

Keywords

  • EGFR mutation
  • gefitinib
  • non-small-cell lung cancer
  • overall survival
  • platinum doublet chemotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. / Yoshioka, H.; Shimokawa, M.; Seto, T.; Morita, S.; Yatabe, Y.; Okamoto, I.; Tsurutani, J.; Satouchi, M.; Hirashima, T.; Atagi, S.; Shibata, K.; Saito, H.; Toyooka, S.; Yamamoto, N.; Nakagawa, K.; Mitsudomi, T.

In: Annals of Oncology, Vol. 30, No. 12, 01.12.2019, p. 1978-1984.

Research output: Contribution to journalArticle

Yoshioka, H, Shimokawa, M, Seto, T, Morita, S, Yatabe, Y, Okamoto, I, Tsurutani, J, Satouchi, M, Hirashima, T, Atagi, S, Shibata, K, Saito, H, Toyooka, S, Yamamoto, N, Nakagawa, K & Mitsudomi, T 2019, 'Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer', Annals of Oncology, vol. 30, no. 12, pp. 1978-1984. https://doi.org/10.1093/annonc/mdz399
Yoshioka, H. ; Shimokawa, M. ; Seto, T. ; Morita, S. ; Yatabe, Y. ; Okamoto, I. ; Tsurutani, J. ; Satouchi, M. ; Hirashima, T. ; Atagi, S. ; Shibata, K. ; Saito, H. ; Toyooka, S. ; Yamamoto, N. ; Nakagawa, K. ; Mitsudomi, T. / Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. In: Annals of Oncology. 2019 ; Vol. 30, No. 12. pp. 1978-1984.
@article{5ad8284ab49d484aa80348a2dc3376e1,
title = "Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer",
abstract = "Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. Patients and methods: Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. Results: OS events in the G group and CD group were 68 (79.1{\%}) out of 86 and 59 (68.6{\%}) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95{\%} confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95{\%} CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. Conclusion: G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease. This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.",
keywords = "EGFR mutation, gefitinib, non-small-cell lung cancer, overall survival, platinum doublet chemotherapy",
author = "H. Yoshioka and M. Shimokawa and T. Seto and S. Morita and Y. Yatabe and I. Okamoto and J. Tsurutani and M. Satouchi and T. Hirashima and S. Atagi and K. Shibata and H. Saito and S. Toyooka and N. Yamamoto and K. Nakagawa and T. Mitsudomi",
year = "2019",
month = "12",
day = "1",
doi = "10.1093/annonc/mdz399",
language = "English",
volume = "30",
pages = "1978--1984",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer

AU - Yoshioka, H.

AU - Shimokawa, M.

AU - Seto, T.

AU - Morita, S.

AU - Yatabe, Y.

AU - Okamoto, I.

AU - Tsurutani, J.

AU - Satouchi, M.

AU - Hirashima, T.

AU - Atagi, S.

AU - Shibata, K.

AU - Saito, H.

AU - Toyooka, S.

AU - Yamamoto, N.

AU - Nakagawa, K.

AU - Mitsudomi, T.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. Patients and methods: Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. Results: OS events in the G group and CD group were 68 (79.1%) out of 86 and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95% confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. Conclusion: G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease. This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.

AB - Background: Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) gefitinib compared with cisplatin plus docetaxel (CD) as the first-line treatment of stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. This report presents final overall survival (OS) data. Patients and methods: Patients were randomized between G (250 mg/day orally) and cisplatin (80 mg/m2 intravenously) plus docetaxel (60 mg/m2 i.v.), administered every 21 days for three to six cycles. After the exclusion of 5 patients, 172 patients (86 in each group, modified intention-to-treat population) were included in the survival analysis. OS was re-evaluated using updated data (data cutoff, 30 September 2013; median follow-up time 59.1 months). The Kaplan-Meier method and the log-rank test were used for analysis, and hazard ratios (HRs) for death were calculated using the Cox proportional hazards model. Results: OS events in the G group and CD group were 68 (79.1%) out of 86 and 59 (68.6%) out of 86, respectively. Median survival time for G and CD were 34.9 and 37.3 months, respectively, with an HR of 1.252 [95% confidence interval (CI): 0.883-1.775, P = 0.2070]. Multivariate analysis identified postoperative recurrence and stage IIIB/IV disease as independent prognostic factors, with an HR of 0.459 (95% CI: 0.312-0.673, P < 0.001). Median survival time (postoperative recurrence versus stage IIIB/IV disease) were 44.5 and 27.5 months in the G group and 45.5 and 32.8 months in the CD group, respectively. Conclusion: G did not show OS benefits over CD as the first-line treatment. OS of patients with postoperative recurrence was better than that of stage IIIB/IV disease, even though both groups had metastatic disease. This study was registered with UMIN (University Hospital Medical Information Network in Japan), number 000000539.

KW - EGFR mutation

KW - gefitinib

KW - non-small-cell lung cancer

KW - overall survival

KW - platinum doublet chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85077402184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077402184&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdz399

DO - 10.1093/annonc/mdz399

M3 - Article

C2 - 31553438

AN - SCOPUS:85077402184

VL - 30

SP - 1978

EP - 1984

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -